Chi-Un Choe1, Elina Petersen2, Susanne Lezius3, Bastian Cheng4, Robert Schulz4, Carsten Buhmann4, Monika Pötter-Nerger4, Günter Daum5, Stefan Blankenberg6, Christian Gerloff4, Edzard Schwedhelm7, Tanja Zeller6. 1. Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: cchoe@uke.de. 2. Epidemiological Study Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 3. Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 4. Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 5. Department of Vascular Medicine, University Heart and Vascular Center, Hamburg, Germany; German Center of Cardiovascular Research (DZHK); Partner Site Hamburg/Lübeck/Kiel, Hamburg, Germany. 6. German Center of Cardiovascular Research (DZHK); Partner Site Hamburg/Lübeck/Kiel, Hamburg, Germany; Department of General and Interventional Cardiology, University Heart and Vascular Center, Hamburg, Germany. 7. German Center of Cardiovascular Research (DZHK); Partner Site Hamburg/Lübeck/Kiel, Hamburg, Germany; Institute of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Abstract
OBJECTIVES: In prospective cohort studies different blood lipid fractions have been identified as risk factors of Parkinson's disease (PD). However, data relating lipoproteins to disease phenotypes and progression in advanced PD patients are sparse. Therefore, we assessed the most common lipoproteins in a case-control design and evaluated their associations with motor and cognitive function and decline in PD patients. METHODS: Triglycerides, LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), and lipoprotein a (Lp(a)) were analyzed in 294 PD patients of the MARK-PD study cohort and 588 controls matched for age, sex and cardiovascular risk factors. In PD patients, motor (MDS-UPDRS III, Hoehn-Yahr stage) and cognitive function (MoCA) were examined. In a sub-cohort (n = 98 patients), baseline lipid levels were correlated with motor and cognitive disease progression during a follow-up period of 523 ± 199 days. RESULTS: At baseline, HDL-C levels were lower in PD patients compared to matched controls after adjustment. We observed a very weak association of Lp(a) levels with UDPRS III scores. In cross-sectional analyses, no other lipid fraction revealed a significant and consistent association with motor or cognitive function. During follow-up, no lipid fraction level was associated with motor or cognitive progression. CONCLUSION: In advanced PD, there is no strong and consistent association of lipid levels with motor or cognitive function and decline.
OBJECTIVES: In prospective cohort studies different blood lipid fractions have been identified as risk factors of Parkinson's disease (PD). However, data relating lipoproteins to disease phenotypes and progression in advanced PD patients are sparse. Therefore, we assessed the most common lipoproteins in a case-control design and evaluated their associations with motor and cognitive function and decline in PD patients. METHODS: Triglycerides, LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), and lipoprotein a (Lp(a)) were analyzed in 294 PD patients of the MARK-PD study cohort and 588 controls matched for age, sex and cardiovascular risk factors. In PD patients, motor (MDS-UPDRS III, Hoehn-Yahr stage) and cognitive function (MoCA) were examined. In a sub-cohort (n = 98 patients), baseline lipid levels were correlated with motor and cognitive disease progression during a follow-up period of 523 ± 199 days. RESULTS: At baseline, HDL-C levels were lower in PD patients compared to matched controls after adjustment. We observed a very weak association of Lp(a) levels with UDPRS III scores. In cross-sectional analyses, no other lipid fraction revealed a significant and consistent association with motor or cognitive function. During follow-up, no lipid fraction level was associated with motor or cognitive progression. CONCLUSION: In advanced PD, there is no strong and consistent association of lipid levels with motor or cognitive function and decline.
Authors: Megan C Bakeberg; Anastazja M Gorecki; Jade E Kenna; Alexa Jefferson; Michelle Byrnes; Soumya Ghosh; Malcolm K Horne; Sarah McGregor; Rick Stell; Sue Walters; Frank L Mastaglia; Ryan S Anderton Journal: Front Aging Neurosci Date: 2021-06-11 Impact factor: 5.750